(NASDAQ: ADVM) Adverum Biotechnologies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.23%.
Adverum Biotechnologies's earnings in 2025 is -$183,874,000.On average, 3 Wall Street analysts forecast ADVM's earnings for 2025 to be -$107,159,815, with the lowest ADVM earnings forecast at -$142,062,770, and the highest ADVM earnings forecast at -$77,221,712. On average, 3 Wall Street analysts forecast ADVM's earnings for 2026 to be -$47,073,768, with the lowest ADVM earnings forecast at -$67,359,157, and the highest ADVM earnings forecast at -$26,859,726.
In 2027, ADVM is forecast to generate -$67,568,998 in earnings, with the lowest earnings forecast at -$67,568,998 and the highest earnings forecast at -$67,568,998.